Department of Pharmacology, Xinjiang Medical University, 830054 Urumqi, Xinjiang, People׳s Republic of China; Department of Pharmacology, Universite de Bordeaux, F-33076 Bordeaux Cedex, France.
Department of Pharmacology, Xinjiang Medical University, 830054 Urumqi, Xinjiang, People׳s Republic of China.
J Ethnopharmacol. 2015 Jan 15;159:184-8. doi: 10.1016/j.jep.2014.11.006. Epub 2014 Nov 13.
Abnormal Savda Munziq (ASMq) is a standard herbal preparation used in Uyghur traditional medicine to fight chronic diseases including cardiovascular, but its specific effects on thrombosis and platelet aggregation are unknown.
Rabbit platelets were incubated with ASMq extract (10, 20, 40 µg/ml) for 15, 30, or 60 min, and aggregation was induced with ADP and collagen. In vivo, ASMq extract 2.97 g/kg, 5.94g/kg, 11.88 g/kg per os daily for 15 days were tested on thrombus wet weight in a rat model of arterio-venous bypass thrombosis. Plasma thromboxane B2 (TXB2) and 6-keto-PGF1a (6PG) were measured by radioimmunoassay. Aspirin (12 µg/ml and 5mg/kg) and saline were used as control in both experiments.
ASMq inhibited ADP and collagen-induced aggregation in vitro in a dose-dependent manner that increased over time, to a maximum of 6.4 ± 1.3% and 21.6 ± 4.0% for ADP and collagen, respectively, at one hour׳s incubation with the highest concentration, whereas the effects of aspirin (34.5 ± 2.2% and 41.9 ± 2.5%, respectively) were stable over time. In vivo, ASMq inhibited thrombus formation dose-dependently, by 70% at the highest dose, compared to 67% with aspirin. ASMq essentially did not change prostaglandin production, compared to the clear inhibition by aspirin.
Abnormal Savda Munziq extract inhibits dose-dependent platelet aggregation with ADP or collagen in vitro and thrombosis in vivo to values similar to those of aspirin, though unlike aspirin this effect does not seem mediated by an inhibition of cyclo-oxygenase.
异常黑胆质成熟剂（ASMq）是一种用于维吾尔传统医学治疗心血管等慢性疾病的标准草药制剂，但它对血栓形成和血小板聚集的具体作用尚不清楚。
将兔血小板与 ASMq 提取物（10、20、40μg/ml）孵育 15、30 或 60min，并用 ADP 和胶原诱导聚集。在体内，对动脉-静脉旁路血栓形成大鼠模型进行了 ASMq 提取物 2.97g/kg、5.94g/kg、11.88g/kg 每日口服 15 天的血栓湿重试验。采用放射免疫法测定血浆血栓素 B2（TXB2）和 6-酮-PGF1a（6PG）。阿司匹林（12μg/ml 和 5mg/kg）和生理盐水在两个实验中均作为对照。
ASMq 以剂量依赖性方式抑制 ADP 和胶原诱导的体外聚集，随着时间的推移而增加，在 1 小时孵育时，最高浓度分别达到 6.4±1.3%和 21.6±4.0%，而阿司匹林（分别为 34.5±2.2%和 41.9±2.5%）的作用则随时间保持稳定。在体内，ASMq 抑制血栓形成呈剂量依赖性，最高剂量下抑制率为 70%，与阿司匹林的 67%相似。与阿司匹林明显抑制前列腺素生成相比，ASMq 基本不改变前列腺素生成。
异常黑胆质成熟剂提取物在体外通过 ADP 或胶原抑制剂量依赖性血小板聚集，在体内抑制血栓形成，其作用与阿司匹林相似，但与阿司匹林不同，这种作用似乎不是通过抑制环氧化酶介导的。
